Search Press releases Keywords From To 13 Oct 2023 UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023 Read More 12 Oct 2023 Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa Read More 9 Oct 2023 UCB to Present New Bimekizumab Data in Hidradenitis Suppurativa, Psoriasis and Psoriatic Arthritis at EADV 2023 Read More 25 Sep 2023 UCB announces approval of RYSTIGGO[®] (rozanolixizumab) and ZILBRYSQ[®] (zilucoplan) for the treatment of adult patients with generalized myasthenia gravis in Japan Read More 19 Sep 2023 UCB Provides Update on U.S. Regulatory Review of Bimekizumab Read More 15 Sep 2023 UCB receives CHMP positive opinion of zilucoplan for the treatment of adults with generalized myasthenia gravis in Europe Read More Pagination First page Previous page Previous … Page 30 Page 31 Page 32 Page 33 Current page 34 Page 35 Page 36 Page 37 Page 38 … Page 34 of 67 Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
